Cargando…

Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients

BACKGROUND: The optimal dose of tinzaparin for prophylaxis in obese medical patients is not well defined. OBJECTIVES: To evaluate the anti-Xa activity in obese medical patients on tinzaparin prophylaxis adjusted for actual bodyweight. METHODS: Patients with a body mass index of ≥30 kg/m(2) treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfrepper, Christian, Koch, Elisabeth, Weise, Maria, Siegemund, Roland, Siegemund, Annelie, Petros, Sirak, Metze, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975291/ https://www.ncbi.nlm.nih.gov/pubmed/36876282 http://dx.doi.org/10.1016/j.rpth.2023.100054

Ejemplares similares

Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system
por: Pfrepper, Christian, et al.
Publicado: (2020)

Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
por: Metze, Michael, et al.
Publicado: (2020)

Gerinnungsdiagnostik im klinischen Alltag – Teil 2: Überwachung von Antikoagulanzientherapien, neu aufgetretene Thrombozytopenie und Thrombophilie
por: Metze, Michael, et al.
Publicado: (2022)

Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
por: Engelen, Matthias M., et al.
Publicado: (2022)

The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study
por: Karamouzis, Michalis V., et al.
Publicado: (2021)

The Role of Tinzaparin in Oncology
por: Dimakakos, Evangelos P., et al.
Publicado: (2017)

Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study
por: Akinosoglou, Karolina, et al.
Publicado: (2022)

In Surgical Colon Cancer Patients Extended-Duration Thromboprophylaxis (30 days) with the Highest Dose of Tinzaparin (4,500 IU s.c./q.d.) Normalizes the Postoperative VEGF Levels
por: Mitsis, Michail, et al.
Publicado: (2017)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?
por: Johansen, Kristian B, et al.
Publicado: (2013)

Predictors for thromboembolism in patients with cholangiocarcinoma
por: Pfrepper, Christian, et al.
Publicado: (2021)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

Heparin/tinzaparin-sodium: Lack of efficacy: 3 case reports
Publicado: (2020)

Tinzaparin-sodium: Bleeding and deep venous thrombosis: case report
Publicado: (2022)

Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review
por: Fioretti, Agnese Maria, et al.
Publicado: (2022)

10% Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage
por: Siegemund, Martin
Publicado: (2009)

Predictors for blood loss and transfusion frequency to guide blood saving programs in primary knee- and hip-arthroplasty
por: Pempe, Christina, et al.
Publicado: (2021)

Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis
por: Mahmood, Dana, et al.
Publicado: (2010)

Extended-Duration Treatment of Superficial Vein Thrombosis of the Lower Limbs with Tinzaparin
por: Nikolakopoulos, Konstantinos M., et al.
Publicado: (2018)

Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications
por: Helfer, Hélène, et al.
Publicado: (2019)

Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review
por: Vathiotis, I. A., et al.
Publicado: (2021)

Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin
por: Karathanos, Christos, et al.
Publicado: (2022)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Single-Bolus Tinzaparin Anticoagulation in Extended Hemodialysis Session: A Feasibility Study
por: Harvey, Benoît, et al.
Publicado: (2023)

The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways
por: Gockel, Lukas Maria, et al.
Publicado: (2018)

Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?
por: Wijaya, Indra, et al.
Publicado: (2020)

Overuse and underuse of thromboprophylaxis in medical inpatients
por: Kocher, Barbara, et al.
Publicado: (2023)

The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
por: Mueller, Thomas, et al.
Publicado: (2017)

Spontaneous gall bladder haemorrhage in a renal dialysis patient following haemodialysis with tinzaparin
por: Borman, Natalie, et al.
Publicado: (2010)

Tinzaparin—a review of its molecular profile, pharmacology, special properties, and clinical uses
por: Amerali, Marina, et al.
Publicado: (2022)

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
por: Garcia-Romeu, Albert, et al.
Publicado: (2021)

A prophylactic subcutaneous dose of the anticoagulant tinzaparin does not influence qPCR-based assessment of circulating levels of miRNA in humans
por: Nilsson, Abraham, et al.
Publicado: (2022)

Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight
por: Fox, Ashley N., et al.
Publicado: (2019)

Thromboprophylaxis for medical inpatients with coronavirus disease 2019
por: Dalager-Pedersen, M., et al.
Publicado: (2020)

Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer
por: Sarantis, Panagiotis, et al.
Publicado: (2021)

Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
por: Muñoz-Rivas, Nuria, et al.
Publicado: (2022)

In Reply to Bevelacqua et al
por: Finazzi, Tobias, et al.
Publicado: (2021)

Acute and Long-Term Cardiovascular Complications among Patients with Sepsis and Septic Shock
por: Merdji, Hamid, et al.
Publicado: (2022)

Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein
por: Marini, Irene, et al.
Publicado: (2017)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_acmh8p9sht6q6flnop4jhk9baf